Flare Therapeutics Appoints Stephen L. Eck, M.D., Ph.D., as Chief Medical Officer [Yahoo! Finance]
MacroGenics, Inc. (MGNX)
Last macrogenics, inc. earnings: 11/6 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.macrogenics.com
Company Research
Source: Yahoo! Finance
factors to discover precision medicines for oncology and other therapeutic areas, today announced the appointment of Stephen L. Eck, M.D., Ph.D., as Chief Medical Officer. Dr. Eck brings more than three decades of oncology drug discovery and development leadership across academia, biotechnology and large pharmaceutical companies. “Throughout my career, I've been driven by the goal of bringing better therapies to people living with cancer,” said Dr. Eck. “Flare Therapeutics is advancing a highly differentiated clinical-stage pipeline grounded in novel biology, including FX-909, a novel PPARG inhibitor designed to target the underlying driver of urothelial cancer, and FX-111, which uniquely targets AR ON – the transcriptionally activated androgen receptor – to address prostate cancer across all stages of disease. I'm excited to work with the team to thoughtfully and rigorously advance these programs through the clinic.” In his new role, Dr. Eck will lead Flare Therapeutics' clinical
Show less
Read more
Impact Snapshot
Event Time:
MGNX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MGNX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MGNX alerts
High impacting MacroGenics, Inc. news events
Weekly update
A roundup of the hottest topics
MGNX
News
- MacroGenics (NASDAQ:MGNX) was downgraded by analysts at Zacks Research from a "strong-buy" rating to a "hold" rating.MarketBeat
- December 2025 Penny Stocks Worth Watching [Yahoo! Finance]Yahoo! Finance
- MacroGenics (NASDAQ:MGNX) had its "sell (d-)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- MacroGenics to Participate in the 8th Annual Evercore Healthcare Conference [Yahoo! Finance]Yahoo! Finance
- MacroGenics to Participate in the 8th Annual Evercore Healthcare ConferenceGlobeNewswire
MGNX
Earnings
- 11/12/25 - Beat
MGNX
Analyst Actions
- 11/3/25 - HC Wainwright
MGNX
Sec Filings
- 1/6/26 - Form SCHEDULE
- 12/10/25 - Form 4
- 11/20/25 - Form 8-K
- MGNX's page on the SEC website